Annual Report to Shareholders
Released
Released
Announcement PDF
Annual
Report
2024
ASX: RCE, FSE: R9Q
Recce Pharmaceuticals Ltd
(ASX: RCE, FSE: R9Q)
is developing a New Class of Synthetic AntiInfectives designed to address the urgent global
health problems of antibiotic-resistant superbugs
and emerging viral pathogens.
Recce’s anti-infective pipeline includes three
patented, broad-spectrum, synthetic polymer antiinfectives: RECCE® 327 (R327) as an intravenous
and topical therapy that is being developed for the
treatment of serious and potentially life-threatening
infections due to Gram-positive and Gram-negative
bacteria, including their superbug forms; This lead
asset is currently undergoing multiple clinical studies.
RECCE® 435 (R435) as an orally administered therapy
for bacterial infections; and RECCE® 529 (R529)
for viral infections. Through their multi-layered
mechanisms of action, Recce’s anti-infectives have
the potential to overcome the processes utilised by
bacteria to overcome resistance – a current challenge
facing existing antibiotics.
The World Health Organization (WHO) added R327,
R435, and R529 to its list of antibacterial products
in clinical development for priority pathogens,
recognising Recce’s efforts to combat antimicrobial
resistance. The Food and Drug Administration
(FDA) has rewarded R327 Qualified Infectious
Disease Product designation under the Generating
Antibiotic Initiatives Now (GAIN) Act, providing
Fast Track Designation and 10 years of market
exclusivity post approval. R327 is also included on
The Pew Charitable Trusts’ Global New Antibiotics in
Development Pipeline as the sole synthetic polymer
and sepsis drug candidate in development.
Recce wholly owns the automated manufacturing of
its active, supporting current clinical trials. Recce’s
anti-infective pipeline aims to address synergistic,
unmet medical needs by leveraging its unique
technologies.
Contents
2
Business Highlights
4 Letter from Chairman
6
Letter from CEO
8
Overview of Company Activities
10 Intravenous Programs
11 Topical Programs
14 Pre-clinical
18 Board of Directors and Key Management Personnel
19 Financial Report
79 Corporate Directory
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
16 Conference Engagement
1
Business Highlights
Listed below are the main corporate developments
for the Financial Year (FY24) ending 30 June 2024.
Commercial and Operational
RECCE® 327 (R327) added to the World Health
Organization’s list of Antibacterial Products in
Clinical Development
Delivered the Opening R&D Address at the World
Antimicrobial Resistance (AMR) Congress 2023
Presented abstracts at the Military Health System
Research Symposium (MHSRS) 2023 and American
Society for Clinical Pharmacology & Therapeutics
(ASPCT) 2024
Received a total of A$11.17m from R&D Rebate
Advance Payments
Secured Capital Raise of up to ~A$12.4m (Q3 CY23)
Australian Government awarded AUD $54,947,284
Advanced Overseas Finding across Recce infectious
disease portfolio
Established strategic partnership in South-East Asia
to accelerate clinical anti-infective portfolio
Regulatory
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
2
New Family 4 patent granted for RECCE® Anti-Infectives
in Australia, Canada and Israel
New Family 2 patent granted for RECCE® Anti-Infectives
in China
RECCE® Trademark registered in Vietnam and Canada
Completed the production of 5,000 manufactured R327
doses per week, under GMP for each campaign
Clinical and Pre-Clinical
Urinary Tract Infection (UTI)/Urosepsis
•
Completed Phase I intravenous (I.V.) clinical trial of R327 in 80 human subjects
(60 received R327, 20 placebo) and reported positive independently verified results
•
Completed Phase I/II UTI/Urosepsis Rapid Infusion Trial and reported positive efficacy
data from the urine of dosed participants
•
Dosed five cohorts across various infusion times (15, 20, 30 and 45 minutes)
at 2,500-4,000 mg of R327
•
R327 was shown to be safe and well-tolerated in healthy participants
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
•
Received Human Research Ethics Committee (HREC) approval received to commence a
Phase II clinical trial assessing R327 as a topical, broad-spectrum gel applied to
patients with ABSSSIs
Diabetic Foot Infections (DFI)
•
Reported positive human efficacy data from Phase I/II trial evaluating R327 Gel (R327G)
in patients with DFIs and expanded trial to additional domestic and international sites
Burn Wound Infections
•
Completed a Stage 1 data analysis in Phase I/II trial of R327 in patients with burn wound
infections
•
Received US$2 million (approx. A$3 million) in grant funding from the U.S. Department
of Defense for Recce’s burn wound program
Pre-Clinical
•
Reported positive pre-clinical results of R327 against Neisseria gonorrhoeae, Escherichia coli
and Mycobacterium abscessus lung infections
•
Recce to continue its strategic partnership with Murdoch Children’s Research Institute
(MCRI)
Therapeutic Goods Administration (TGA) Special Access Scheme
Dosed five (5) patients experiencing complex, resistant infections – surgery/amputation
was averted, and wound healing was observed across all patients
•
Reported positive results from patients with patients suffering antibiotic-resistant
Gram-positive and Gram-negative bacterial infections, treated with treated with R327G
under the TGA Special Access Scheme – Category A
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
•
3
Letter from the
Chairman
Dear Shareholders,
We are pleased to present Recce Pharmaceuticals’ annual report
for the year ended 30 June 2024. The year has been marked by
significant achievements and progress in Recce’s research and
clinical development programs, manufacturing capabilities and
human resources. One of the most gratifying highlights was the
recognition of one of Recce’s research and development programs
by the United States Government Department of Defense that
awarded the Company a US$2 million grant to study burn
wound infections.
As the only new class of antibiotic in the
past 40 years, the opportunity for our
assets to transform public health and
medical practice is significant.
Clinical progress
It is important to bring attention that the threat of antibiotic
resistance continues to grow at alarming rates with recalcitrant
infections continuing to rise dramatically in certain regions of
the world. Addressing this crisis requires a multifaceted, global
approach. Recce firmly believes the need for a paradigm shift in
the approach to new antimicrobial treatments. Our novel synthetic
anti-infective platform represents a potential critical advance in this
ongoing silent battle.
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
4
To this end, we are working diligently to advance the clinical
development of our synthetic anti-infective compounds highlighted
this year by impressive initial safety and efficacy data. Recce has
made significant strides in the clinical and commercial development
of its lead candidate, RECCE® 327 (R327). The completion of our
Phase I/II rapid infusion trial and subsequent release of safety and
efficacy data was a major company milestone achieved this period.
These results from the first new class of antibiotic in the past
40 years underscore the potential of our approach and the
opportunity for our assets to transform public health and medical
practice is significant.
The release of this data generated global interest from medical opinion leaders with the team continuing to
capitalise on this interest as Recce prepares to initiate a number of late-stage clinical trials.
The Company also released five patient case studies, with R327G treating patients suffering from life threatening
infections. This was conducted through the Therapeutic Goods Associations (TGA) Special Access Scheme Category A. The scheme gives qualified medical practitioners use of unapproved antibiotic treatments for
complex life-threatening infections not responding to existing treatments.
Further global recognition of our technology’s unique potential came with the World Health Organization (WHO)
citing Recce in its yearly report on Antibacterial Products in Clinical Development. R327 has been defined by the
WHO as an adenosine triphosphate (ATP) production disruptor and is the only compound under this category.
The WHO has classified Recce’s anti-infective compounds as critical to helping combat one of the most urgent
public health challenges of our time. The UK Government Innovation Agency’s AMR Mission 2024 also recognised
Recce’s significant contributions to antimicrobial resistance research and development (R&D).
We approach our work with a sense of urgency, knowing the importance of the task. By leveraging novel
mechanisms of action, overcoming existing resistance pathways, enhancing efficacy, expanding the treatment
arsenal and enabling scalable production, Recce’s revolutionary synthetic antibiotics and applications provide a
multifaceted approach to addressing the problem.
Manufacturing foundations for growth
In 2023 Recce’s manufacturing team demonstrated the ability to manufacture 5,000 doses of R327 per week
under Good Manufacturing Practice (GMP). This marks a first for Recce’s full-spectrum manufacturing capability
including demonstrating the versatile, reproducible nature of its patented manufacturing process. In the coming
year, our expanded manufacturing capabilities will be able to match the output required to supply our present and
anticipated clinical trials ahead.
Our people and future prospects
The calibre of talent at Recce is impressive. As the business continues to deliver results, we are able to attract more
specialists in the field with the experience to help take the company through its next phase of growth.
The coming year is shaping up to be another significant one for Recce. We have a clear plan, an exciting clinical
pipeline, a strong balance sheet and a team of dedicated professionals with the skills, experience and motivation to
make a global impact.
Finally, and most importantly, I want to thank all our shareholders, our clinical and business partners, and our
growing dedicated team for their unwavering support and commitment to this exciting challenge. This collective
commitment gives us the best possible chance of ensuring our future successes.
Sincerely,
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
Dr John Prendergast
Executive Chairman
5
Letter from the
CEO
I am pleased to present the commercial initiatives undertaken
by Recce in FY24. To support our clinical progress, the Company
has materially strengthened its financial, commercial, intellectual
property and global strategic partnerships in response to the clinical
advancements made over the financial year.
Intellectual property is crucial for earlystage medical innovators with a global
focus like Recce. The Company’s extensive
and robust intellectual property portfolio
underlines the value of its assets and
potential future success.
Funding and financial support
The Company’s commitment to fiscal responsibility is evident with
sufficient capital to fund priority pipeline opportunities.
Managing Recce’s funding needs is a critical function and during
the reporting period our active focus was on securing capital to
progress clinical milestones where Recce has a clear competitive
advantage.
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
6
Government grants and strategic partnerships also provide Recce
with non-dilutive capital to fund its programs. Supporting that,
Recce received an Advanced Overseas Finding of A$54.94m across
the infectious disease portfolio from the Australian Government,
extending our R&D rebates from locally, to globally and assuring
the rebate status to support our research and development costs.
It is one of the largest awarded in Australian history as a pillar of
the R&D Tax Incentive Program administered by the Australian
Government.
A new initiative was established with Sydney-based Endpoints
Capital, which provided the business with an advance payment
of A$11.17m against R&D refunds.
An overseas R&D rebate of A$98,428 from the Canadian
Government was received to support research and development
along with US$2m (approx. A$3m) from the US Department of
Defense (Army) to facilitate the development of our burn
wound program.
The Company has a clear vision for the future and the capital raise of A$12.4m completed in Q3 CY23 has provided
the funding to implement the next phase of clinical development for Recce’s clinical pipeline.
Recce’s ability to raise the required capital is a direct result of extensive market engagement and investor outreach
efforts throughout the year. Investors and our existing shareholders have been proven to understand the Company,
its growth strategy and commercial potential.
Intellectual property and recognition
Intellectual property is crucial for early-stage medical innovators with a global focus like Recce. Recce is the 100%
owner of >40 granted patents among an extensive and robust intellectual property portfolio, underlining the value
of its assets and potential future success.
During the reporting period Recce furthered its patent estate, through the grant of patents in Australia, Israel,
Canada (Family 4), and China (Family 2) for its anti-infective drugs, significantly strengthening its position in these
major markets.
Strategic partnerships and collaborations
Recce has been commercially active in terms of collaborations and partnerships with leading firms in the
biopharmaceutical and drug manufacturing fields.
One of the most significant strategic partnerships developed this year was our collaboration and signed
Memorandum of Understanding (MoU) with Indonesia’s PT Etana Biotechnologies in Jakarta.
Etana is a significant player in the Indonesian and Southeast Asian biopharmaceutical landscape. Etana is a leading
contributor to the Indonesian government’s health initiatives and Recce looks forward to sharing developments
of the partnership over the coming year.
The Company also established several important relationships with leading clinical research partners and hospitals
in Australia who play a key role in the expansion and coordination of our clinical programs.
We continued our engagements with the prestigious Murdoch Children’s Research Institute in Melbourne which
saw the establishment of a dedicated anti-infective research unit, producing very promising pre-clinical data.
Tests to date have shown efficacy against a range of hard-to-treat World Health Organization (WHO) drug-resistant
priority pathogens.
We look forward to sharing the next phase of our journey with you and thank shareholders for their continued
support.
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
James Graham,
Managing Director & Chief Executive Officer
7
Overview of
Company Activities
Recce has made substantial progress in its clinical programs, completing, and
expanding, new trials across multiple indications. The Company’s clinical trials include
both intravenous and topical programs, targeting indications such as UTI/urosepsis,
diabetic foot infections, burn wound infections, and acute bacterial skin and skin
structure infections.
The Company’s key clinical objectives were met, with the completion of multiple clinical
trials, including a Phase I intravenous trial and a Phase I/II UTI/urosepsis rapid infusion trial.
The Company also initiated a Phase II trial evaluating R327 as a topical gel in patients with
acute bacterial skin and skin structure infections (ABSSSI). Recce is preparing to initiate a
Phase III registrational trial in Indonesia, following a signed Memorandum of Understanding
(MoU) with PT Etana Biotechnologies (Etana), a leading Indonesian biomedical organisation.
Recce’s Anti-Infective Research (AIR) Unit at Murdoch Children’s Research Institute
continued to produce strong preclinical data, demonstrating efficacy against multiple
World Health Organization (WHO) priority pathogens, including Mycobacterium abscessus,
Neisseria gonorrhoeae, and Escherichia coli. This efficacy data further supports the potential
of new indications for Recce’s platform technology to progress into the clinic.
Recce has materially strengthened its financial position to progress its ongoing to progress its
ongoing clinical programs and to continue the development of its preclinical portfolio, following
a successful capital raise, raising a total of approximately A$10.7 million (before costs) through
an entitlement offer (A$2.7 million before costs) and placement (A$8 million before costs) to
institutional, sophisticated and professional investors announced 29 September 2023. CEO
James Graham, took up his full entitlement, investing a further A$102.7k into the Company, with
Directors taking up approximately A$110,000 (~250,000 Shares) of entitlement shortfall.
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
8
Asset and
Route of Administration
Indications
R327 Intravenous
UTI/Urosepsis
R327 Topical Gel
Acute Bacterial Skin
and Skin Structure Infections*
US Department
of Defense Program**
Burn Wound Infections
Discovery
Pre-clinical
Phase I
Phase II
Phase III
* Including post-operative infection, wound infections and diabetic foot infections.
** The US Department of Defense has Recommended R327 Gel (R327G) as a topical treatment for Burn Wound Infections for grant funding of USD $2.0 million (AUD 3.0 million).
Market
Strategic Opportunity
in South-East Asia
Recce Pharmaceuticals announced a significant milestone with the signing of a
Memorandum of Understanding (MoU) with PT Etana Biotechnologies, a leading
biomedical organisation in Indonesia. This strategic partnership is designed to
accelerate the clinical development of Recce’s anti-infective treatments in Indonesia,
representing a crucial advancement in the global fight against antimicrobial
resistance.
Supported by both the Australian and Indonesian governments, this
collaboration opens the door to the broader ASEAN region, which
includes 10 member states and a population of approximately 670
million people. Both governments have independently introduced
several support initiatives to propel this historic bilateral effort,
underscoring their commitment to advancing public health through
innovative solutions.
The Indonesian government has further endorsed the partnership
by providing access to hospitals for clinical trials and pre-clinical
research.
The MoU outlines a collaborative effort between both parties to
research, develop, produce, distribute, and commercialise a first-inclass therapeutic with broad-spectrum anti-infective capabilities.
This is intended for potential regulatory approval and use across
Indonesia, and possibly other jurisdictions as agreed by the parties,
to address the critical global health challenge of antimicrobial
resistance.
Recce Pharmaceuticals CEO James Graham (left)
and Indonesian Minister of Health Budi Sadikin (right).
“The global health challenge of antimicrobial resistance is a pressing issue on the world stage.
Indonesia welcomes collaborative initiatives and supports efforts to combat antimicrobial
resistance, including the development of innovative therapeutics for infectious diseases.”
- Mr. Budi Sadikin, Indonesian Minister of Health
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
Indonesian Minister of Health Budi Sadikin addressing Her Excellency Penny Williams and RCE CEO James Graham.
9
Human Clinical Trials
RECCE® 327 (R327) Intravenous (I.V.) Programs
Phase I I.V. Clinical Trial – Completed
The Company completed its first-in-human Phase I trial of R327. The Phase I trial was an ascending dose,
randomised, placebo-controlled, parallel, double-blind, single-dose study.
Following the completion of the study, the Company released positive and independently verified results of
R327 as an I.V. infusion formulation in 80 healthy male subjects (60 received R327, 20 placebo). In concurrence
with the TGA clinical trial regulatory procedures, the recruitment for the study is closed and marked ‘Complete’
with no ‘Serious Adverse Events’ reported.
Summary of results
Safe and well tolerated
at doses up to 6,000mg
given as a 1-hour
intravenous infusion
No Serious Adverse Events
All AE’s mild or moderate
No significant changes
in any laboratory test,
electrocardiogram
(EKG) or telemetry
• Concentrations of R327 increased with dose, half-life (t1/2) increased with dose: 3-5 hours at higher doses
• Urine concentrations were up to 20 times higher than plasma concentrations
• The successful Phase I safety and tolerability study of R327 I.V. in healthy male volunteers has paved the
way for the next stage of R327’s clinical development in sepsis and UTIs
Phase I/II Urinary Tract Infection/Urosepsis Rapid Infusion Clinical
Trial – Completed
The Phase I/II study included 25 participants who received R327 at doses up to 4,000mg as an I.V. formulation
over a range of infusion times (15, 20, 30, and 45 minutes). The highest dose cohort included six participants,
all receiving 4,000mg of R327 over a 20-minute infusion period.
The trial met all primary endpoints, demonstrating R327’s tolerability and significant antibacterial efficacy.
Building on these promising results, the Company plans to commence a Phase II trial to further validate these
findings and explore additional therapeutic indications for R327.
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
10
Key Findings from Clinical Trial at Highest Dose of 4,000 mg of R327 include;
consistent efficacy across participants, clear impact on bacterial growth build-up
over time in human urine, sustained effectiveness and rapid reduction in bacteria
when mixed with urine of participants (ex-vivo).
15 min
20 min
Did you know?
30 min
Antibiotics administered as an I.V. infusion, usually over
30 minutes, have benefits such as savings in nursing time,
reduced costs, and improved safety. The 2021 Surviving Sepsis
Campaign (SCC) guidelines strongly recommend administering
I.V. broad-spectrum antibiotics as soon as possible, preferably
within an hour of sepsis recognition.
45 min
RECCE® 327 (R327) Topical Programs
Phase I/II Diabetic Foot Infection (DFI) Clinical Trial
The Phase I/II trial is an interventional study assessing the safety and efficacy of R327 as a topical broad-spectrum
anti-infective treatment for patients with mild skin and soft tissue DFI. Patients were treated either daily or every
second day for 14 days.
The Company announced that the study achieved its primary endpoint of resolving/curing bacterial infections in
DFIs. Following this success, Recce has expanded clinical sites domestically and internationally in the interest of
accessing a greater patient population.
Summary of patients
Application
Frequency
Age (yrs)/Sex
Wound Location
Pathogen Identified
Clinical Response
Patient 1
Daily
32/M
Left forefoot
lateral aspect
Methicillin-Resistant
S. aureus
Escalated therapy*
Patient 2
Second Daily
55/M
Right hallux
plantar aspect
S. aureus, mixed skin
flora and coliforms
Infection resolved/cured
Patient 3
Second Daily
51/M
Left forefoot
plantar aspect
S. aureus, mixed skin
flora and coliforms
Infection resolved/cured
Patient 4
Daily
70/M
Left forefoot
plantar aspect
Mixed skin flora
Infection resolved/cured
(in half the treatment time)
Patient 5
Daily
64/M
Right hallux
dorsal aspect
Mixed skin flora and
coliforms
Infection resolved/cured
*Patient was on systemic therapy prior to commencing R327 treatment. Patient suffered from several comorbidities and escalated to systemic therapy.
“We are pleased that the Phase I/II clinical trial has met all primary endpoints, and
produced efficacy data to support R327 to be used as topical agent.”
- James Graham, CEO
(18 January 2024)
Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Clinical Trial
The Company received Human Research Ethics Committee (HREC) approval
to commence a Phase II trial assessing R327 as a topical, broad-spectrum
gel applied to patients with ABSSSIs.
This ethics approval allows the Company to combine the clinical studies of
DFIs, wound infections, and more under one essential centralised regulatory
category of ABSSSI for a broad range of unmet medical needs in the topical
bacterial infection landscape. This centralised study approach to the broad
category of ABSSSI has been made possible by building upon and validating
study data to date, including compelling patient outcomes under the TGA
Special Access Scheme Category A initiatives. The study aims to evaluate
the clinical efficacy and toxicity of R327G.
The global ABSSSI treatment
market size was valued
at US$7.3B in 2018 and is
projected to reach US$26B
by 2032, representing a
CAGR of 9.5% between
2019 and 2032.
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
The Phase II trial is an open-label, efficacy study and exploratory evaluation
of the systemic bioavailability of single and/or multiple doses of R327 topical
gel applied to ABSSSIs. The study aims to provide critical data on R327
Gel’s effectiveness in treating a broad range of ABSSSI indications. ABSSSI
refers to a bacterial infection of the skin and its related tissues, such as DFI,
necrotizing fasciitis, and post-operative wound infections.
11
Phase I/II Topical Burn Wound Infection
Clinical Trial – Stage 1 Completed
The data analysis is complete for the Phase I/II trial of R327 in patients with
burn wound Infections.
Clinicians reported a visible reduction in bacterial infection within the first 24
hours of R327 treatment, demonstrating broad-spectrum antibiotic activity
against Gram-positive and Gram-negative pathogens listed on the WHO
Priority Pathogen list of antibiotic-resistant bacteria, defined as multidrugresistant and difficult-to-treat. All patients treated with R327 showed good
indications of safety and tolerability to the compound.
United States Department of Defense Grants
US$2 million for RECCE® 327 Gel
The U.S. Department of Defense awarded Recce a substantial grant of
US$2 million to accelerate the development of R327G, emphasising its
potential in acute treatment scenarios, particularly in military settings.
This funding underscores the innovative nature of R327G as a synthetic
anti-infective designed to rapidly resolve burn wound infections and
minimise the onset of bacteraemia complications, such as sepsis.
The grant, awarded through the US Department of Defense
Congressionally Directed Medical Research Programs (CDMRP),
highlights R327G’s potential to replace traditional antimicrobial dressings
and enhance the quality of care for military personnel.
This recognition reinforces the Company’s commitment to advancing
medical solutions critical to military and civilian populations.
Did you know?
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
12
Aggressive infection is the leading cause of death and
morbidity of burn wound sufferers. The most relevant
and dangerous of burn wound infections are those involving
Staphylococcus aureus, a Gram-positive bacteria located
on the skin and mucous membranes (most often the
nasal area).
Therapeutic Goods Administration (TGA) Special Access Scheme –
Category A
The Company reported on five cases under the TGA SAS-Category A. In this program, R327G was utilised by a
qualified medical practitioner in patients suffering antibiotic-resistant Gram-positive and Gram-negative bacterial
infections.
Patient
Patient A
Patient B
Patient C
Patient D
Patient E
Age (yrs)/Sex
Wound Details
Clinical Response (Post R327G Treatment)
70-75/M
Puncture wound from metal spike.
Unresponsive to all prior antibiotics,
infection spreading, preparing for surgery.
• 24 hours after one dose of R327G, the infection
clinically responded (no pre-treatment debridement
needed).
• Redness and swelling reduced, no stinging reported.
• 30 days post-treatment, wound successfully healed
and closed.
72/M
Type 2 diabetes, unresponsive to all prior
antibiotics. Peripheral Vascular disease and
neuropathy.
• Day 7: redness and swelling minimised; wound
healing and drying.
• Day 10: no infection, no pus, wound clearing and
healing.
• Day 14: significant improvement, well tolerated.
51/F
Significant wound infection post-ankle infusion
surgery. Diagnosed with arthritis in the right
ankle due to talar avascular necrosis.
• Day 7: redness and swelling minimised, wound
drying.
• Day 14: no bacterial growth around wound.
• Day 21: wound healed, closed, and dried with
no infection.
Involved in a motor bike accident in 2017, was
required to have an amputation above the knee.
The patient received an osseointegration (bone
ingrowth metal implant). Recurrent infection on
the left femoral (thigh).
• Day 3: redness and swelling minimised, wound
healing and drying.
• Day 14: wound dried, improved with no redness
or swelling.
Osteomyelitis (serious infection of the bone) on
his left big great toe, not responding to
antibiotics.
• Day 3: wound drying, infection clearing, toe
responding well.
• Day 7: wound dried, no biofilm, swelling reduced.
• Surgical intervention averted.
51/M
84/M
GMP Manufacturing Capabilities Supporting Clinical Trials
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
The Company completed the production of 5,000 R327 doses per
week under the Good Manufacturing Practice (GMP) campaign.
Due to the increased demand for R327 required for clinical
studies, producing 5,000 doses of R327 per week is a significant
achievement that provides surplus sample material for the
TGA Special Access Scheme, Phase I, Phase II, and anticipated
registrational Phase III opportunities ahead.
13
Pre-Clinical
Pre-Clinical Efficacy Results Produced by Murdoch Children’s Research
Institute (MCRI) Anti-Infective Research (AIR) Unit
The Company has continued its strategic partnership with Murdoch Children’s Research Institute, following key
pre-clinical efficacy data received for multiple WHO priority pathogens. This data will support clinical trials for
new indications.
Neisseria gonorrhoeae (N. gonorrhoeae)
Study Outline:
Share your feedback
Discover